Court ruling against FDA on off-label promotion could negate new proposals
This article was originally published in Clinica
Executive Summary
A US federal judge has ruled that the FDA's policy blocking medical device and pharmaceutical makers from distributing information on unapproved or off-label uses of their products is a violation of the First Amendment guaranteeing free speech.